Wall Street Zen Upgrades Turn Therapeutics (NASDAQ:TTRX) to “Hold”

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

TTRX has been the topic of a number of other research reports. Weiss Ratings cut shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. WBB Securities raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price target for the company in a research report on Friday, October 23rd. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Finally, LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Turn Therapeutics Price Performance

TTRX stock opened at $10.43 on Friday. The firm has a 50 day moving average of $11.72 and a 200-day moving average of $7.01. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45. The firm has a market capitalization of $318.43 million and a P/E ratio of -35.97.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. As a group, sell-side analysts predict that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TTRX. TD Waterhouse Canada Inc. acquired a new position in Turn Therapeutics in the 3rd quarter valued at about $40,000. Bank of America Corp DE purchased a new stake in Turn Therapeutics in the 2nd quarter valued at about $103,000. Jefferies Financial Group Inc. bought a new stake in Turn Therapeutics during the 2nd quarter valued at $119,000. Bridgewater Advisors Inc. purchased a new stake in Turn Therapeutics in the second quarter worth about $242,000. Finally, BlackRock Inc. bought a new position in Turn Therapeutics during the 2nd quarter worth about $282,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.